Evolus (EOLS) Short term Debt (2017 - 2020)

Evolus' (EOLS) quarterly Short term Debt came in at $74.4 million in Q4 2020, up 2.4% on a QoQ basis from $72.6 million in Q4 2017.

Evolus (EOLS) Short term Debt (2017 - 2020) Analysis & Trends

Evolus (EOLS) has 2 years of Short term Debt data on file, last reported at $74.4 million in Q4 2020.

Quarterly Short term Debt changed N/A year-over-year to $74.4 million in Q4 2020, while the trailing twelve-month figure through Dec 2020 was $74.4 million (changed N/A YoY) and the FY2020 annual result came in at $74.4 million, changed N/A from the prior year.
Short term Debt improved to $74.4 million in Q4 2020, from $72.6 million in the prior quarter.
In the past five years, Short term Debt ranged from a high of $74.4 million in Q4 2020 to a low of $72.6 million in Q4 2017.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Haleon	44.51 Bn	43.55 Bn	-
2	Teva Pharmaceutical Industries	43.52 Bn	39.86 Bn	2.15 Bn
3	Zoetis	32.43 Bn	30.75 Bn	1.05 Bn
4	Takeda Pharmaceutical	28.63 Bn	22.83 Bn	5.10 Bn
5	United Therapeutics	21.87 Bn	19.21 Bn	683.80 Mn
6	Viatris	18.98 Bn	18.09 Bn	1.46 Bn
7	Neurocrine Biosciences	15.43 Bn	15.04 Bn	935.80 Mn
8	Elanco Animal Health	12.02 Bn	11.49 Bn	798.00 Mn
9	Dr Reddys Laboratories	10.14 Bn	9.98 Bn	-
10	Evolus	552.49 Mn	507.32 Mn	57.18 Mn

Download Data

Date	Value
Dec 31, 2020	74.38 Mn
Dec 31, 2017	72.64 Mn